期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用 被引量：2

Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neu- ropsychiatric disorders
原文传递
导出
摘要 y-氨基丁酸A型-苯二氮革（GABArBZ）受体广泛分布于中枢神经系统，是嵌于神经细胞膜上的异质性多肽五聚体，不同的亚单位组合发挥不同的神经抑制性药理作用，如镇静催眠、抗惊厥、抗焦虑等。PET可用于活体内受体结合的研究。GABAA-BZ受体PET显像剂分为拈抗剂、激动剂、反向激动剂3类，其中以拮抗剂显像剂11C-氟马西尼最为成熟，在癫痫、焦虑症、抑郁症、植物状态、成瘾等神经精神疾病中广泛应用。 Gamma-aminobutyric acid type A-benzodiazepine receptors are heterogeneous polypeptide pentamers widely spread in the central nervous system on the neuron membrane. Different subunit combinations educe various neuro-inhibitory pharmacological effects such as sedative, hypnosis, anticonvulsion and anxiolysis. PET can be utilized to study the binding of the receptors in vivo. PET radioligands of gammaaminobutyric acid type A-benzodiazepine receptors can be classified into 3 types： antagonists, agonists and reverse agonists, of which antagonist radiotracer 11C-flumazenil is the most commonly applied in epilepsy, anxiety disorders, depression, vegetative state, addiction and other neuro-psychiatric disorders.
作者 鲍伟奇 邱春 管一晖
机构地区 上海复旦大学附属华山医院PET中心
出处 《国际放射医学核医学杂志》 2012年第1期1-8,共8页 International Journal of Radiation Medicine and Nuclear Medicine
关键词 神经系统疾病 受体 GABA—A 正电子发射断层显像术 Nervous system diseases Receptors, GABA-A Positron-emission tomography
分类号 R817.4 [医药卫生—影像医学与核医学]
  • 相关文献

参考文献54

  • 1朱大年.神经系统功能活动的基本原理//姚泰.生理学.北京:人民卫生出版社,2005:410-411.
  • 2胡刚.镇静催眠药//杨世杰.药理学.北京:人民卫生出版社.2005:196-197.
  • 3Olsen RW, Sieghart W. GABAA receptors: Subtypes provide diver- sity of function and pharmacology. Neuropharmacology, 2009, 56 (1): 141-148.
  • 4Luddens H, Seeburg PH, Korpi ER. Impact of beta and gamma variants on ligand-binding properties of gamma-aminobutyric acid type A receptors. Mol Pharmacol, 1994, 45(5 ): S10-814.
  • 5Wingrove PB, Wafford KA, Bain C, et al. The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Natl Acad Sci USA, 1994, 91 ( 10 ): 4569-4573.
  • 6Korpi ER, Kuner T, Seeburg PH, et al. Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Mol Pharmacol, 1995, 47( 2 ): 283-289.
  • 7Pirker S, Schwarzer C, Wiesehhaler A, et al. GABA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience, 2000, 101(4): 815-850.
  • 8Uusi-Oukari M, Korpi ER. Regulation of GABAA receptor subunit expression by pharmacological agents. Pharmacol Rev, 2010, 62 ( 1 ): 97-135.
  • 9Yee BK, Keist R, yon Boehmer L, et al. A schizophrenia-related sensorimotor deficit links containing GABAA receptors to a dopamine hyperfunction. Proc Natl Acad Sci USA, 2005, 102 (47): 17154-17159.
  • 10Smith SS, Gong QH, Hsu FC, et al. GABA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature, 1998, 392( 6679 ): 926-930.

同被引文献20

  • 1Reiman, E.M. and W.J, Jagust, Brain imaging in the study of Alzheimer's disease. Neuroimage, 2012.61(2): p. 505-16.
  • 2Herholz, K., Perfusion SPECT and FDG-PET. Int Psychogeriatr, 2011. 23 Suppl 2: p. $25-31.
  • 3Caroli, A., et al., Summary metrics to assess Alzheimer disease-related hypometabolic pattern with :SF-FDG PET: head-to- head comparison. J Nucl Med, 2012.53(4): p. 592-600.
  • 4Landau, S.M., et al., Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging, 2011.32(7): p. 1207-18.
  • 5Herholz, K., Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. Biomark Med, 2012.6(4): p. 431-9.
  • 6Quigley, H., S.J. Colloby, and J.T. O'Brien, PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry, 2011.26(10): p. 991-9.
  • 7Nord, M. and L. Farde, Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther, 20 l 1.17(2): p. 97-103.
  • 8Johnson, S., et al., The reduction of RI, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsyehopharmacology, 2011.36(10): p. 2139-48.
  • 9Nikolaus, S., et al., Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders-results from in vivo imaging studies. Rev Neurosci, 2010.21(2): p. 119-39.
  • 10Jones, T. and E.A. Rabiner, The development, past achievements, and future directions of brain PET. J Cereb Blood Flow Metab, 2012.32(7): p. 1426-54.

引证文献2

二级引证文献3

国际放射医学核医学杂志
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部